{"id":963157,"date":"2026-05-14T16:47:36","date_gmt":"2026-05-14T20:47:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-reports-first-quarter-2026-financial-results-and-business-highlights\/"},"modified":"2026-05-14T16:47:36","modified_gmt":"2026-05-14T20:47:36","slug":"sutro-biopharma-reports-first-quarter-2026-financial-results-and-business-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-reports-first-quarter-2026-financial-results-and-business-highlights\/","title":{"rendered":"Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights"},"content":{"rendered":"
\n

\n \u2013 On track to report initial safety, PK and early activity from<\/em>
\n Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 \u2013<\/em>\n <\/p>\n

\n \u2013 Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 program STRO-227, with IND submissions planned in 2026 \u2013<\/em>\n <\/p>\n

\n \u2013 First dual-payload iADC from Sutro\u2019s platform entered the clinic under Astellas collaboration; patient dosing underway \u2013<\/em>\n <\/p>\n

\n \u2013 Strong balance sheet with $202.6 million in cash, cash equivalents and marketable securities as of March 31, 2026; including gross proceeds from the recent capital raise, supporting operations into at least the second quarter of\u00a02028 \u2013<\/em>\n <\/p>\n

SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2026 and recent business highlights.<\/p>\n

\u201cDuring the first quarter, we continued to execute across our clinical and preclinical portfolio, positioning Sutro for key data readouts later this year,\u201d said Jane Chung, Sutro\u2019s Chief Executive Officer. \u201cDose escalation is rapidly progressing in our Phase 1 trial of STRO-004, and we remain on track to report initial safety, pharmacokinetic and early activity data in mid-2026, which we believe will provide important insights into its clinical profile and our platform as a whole. This clinical momentum is reinforced by preclinical data we presented at the recent AACR Annual Meeting, which highlighted the robust and consistent antitumor activity of STRO-004, as well as continued progress across our broader ADC pipeline.\u201d<\/p>\n

\u201cIn parallel, we are advancing our next-generation ADC candidates, STRO-006, targeting ITGB6, and STRO-227, our first wholly-owned dual-payload ADC targeting PTK7, as we work toward IND submissions this year. We are also pleased to see our first partnered dual-payload iADC with Astellas entering the clinic, marking an important validation of our platform\u2019s ability to generate differentiated multi-payload ADCs. With a strengthened balance sheet and continued disciplined execution, we believe we are well positioned to deliver meaningful progress across our programs in 2026.\u201d<\/p>\n

\n
\n Wholly-Owned Pipeline<\/u>
\n <\/strong>\n <\/p>\n

\n STRO-004:<\/strong> Sutro continues to advance its ongoing first-in-human Phase 1 dose-escalation trial of STRO-004, a Tissue Factor (TF)-targeting ADC with a DAR8 Topo1 payload, in patients with advanced solid tumors. The Company expects to report initial clinical data in mid-2026, including safety and tolerability, pharmacokinetic exposure, and early activity data. In preclinical studies, STRO-004 demonstrated a favorable safety profile, including a highest non-severely toxic dose (HNSTD) of 50 mg\/kg in non-human primates, supporting the clinical starting dose of 1 mg\/kg.<\/p>\n

\n STRO-006:<\/strong> Sutro\u2019s next-generation, highly selective integrin \u03b26 (ITGB6)-targeting ADC with a DAR8 Topo1 payload, designed for the treatment of multiple solid tumors. The program continues to advance toward clinical development, with an IND submission anticipated in 2026.<\/p>\n

\n STRO-227:<\/strong> Sutro\u2019s wholly-owned DAR10 dual-payload ADC targeting PTK7, combining MMAE (DAR2) and a Topo1 payload (DAR8) to enable complementary mechanisms of action within a single molecule. The program remains on track for IND submission in 2026 and represents a key component of Sutro\u2019s strategy to expand its pipeline of novel-format dual-payload ADCs.<\/p>\n

\n
\n Next-Generation ADC Collaborations<\/u>
\n <\/strong>\n <\/p>\n

\n Astellas:<\/strong> Two research and development programs are progressing under Sutro\u2019s collaboration with Astellas focused on dual-payload immunostimulatory ADCs (iADCs).<\/p>\n